This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Frederick D. Malkinson, MD, DMD

Arch Dermatol. 1996;132(6):695-696.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN SEPTEMBER 1994, the Food and Drug Administration (FDA) circulated a medical bulletin informing physicians and other health care professionals that several reports (to the FDA) of serious radiation injuries to skin had resulted from prolonged fluoroscopic imaging during interventional therapeutic procedures.¹ Long exposure times, high dose rates, and operators' lack of awareness that the doses used exceeded the threshold for radiodermatitis all were implicated. Several procedures involving fluoroscopic exposure times that were potentially prolonged, repetitious, or both were listed, including percutaneous transluminal angioplasty, radiofrequency cardiac catheter ablation, vascular embolization, stent and filter placement, thrombolytic and fibrinolytic procedures, and percutaneous transhepatic cholangiography for portal decompression. It was emphasized that for single short-term exposures, the threshold dose was about 3 Gy (1 Gy is equivalent to 100 rad) for temporary epilation, 6 to 8 Gy for erythema (at 200 kV), and 15 Gy or higher for moist desquamation, . . . [Full Text PDF of this Article]

Author Affiliations
Department of Dermatology Rush Medical College 1653 W Congress Pkwy Chicago, IL 60612-3833

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?